Blog

The latest thoughts from Medicines Law & Policy partners.

The Power of TRIPS Flexibilities in Medicines Procurement

The government of Malaysia has began to roll out treatment of people infected with the hepatitis C virus (HCV).  Treatment will be a combination of...

Dutch Court Orders AstraZeneca to Pay Damages in Patent Evergreening Case

Today the Dutch court made a long-awaited ruling in the patent evergreening case of health insurance company Menzis versus AstraZeneca. It found that AstraZeneca...

WHO Fair Pricing Forum: Watching for Drug Industry Accountability

by Katrina Perehudoff and Jennifer Sellin Expensive medicines are a ubiquitous challenge from which no government is immune. Excessive price hikes are an urgent human...

Socially Responsible Licensing of Medical Technologies

GENEVA, SWITZERLAND: On 31 October, the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO) held their...

“This week, the medicines were not there”: What is at stake in the pandemic...

Earlier this week I listened to a testimony from a community worker at a maternity ward where HIV-positive women gave birth. 17 babies were...

Cystic Fibrosis Medicines Wars in Europe

Monday 4 February, the UK parliament will debate the issuing of a compulsory licence by the government, called ‘Crown use’, for the cystic fibrosis...

“Mutually agreed terms and conditions,” says it all.

On 4 March, Politico reported that the Polish presidency of the Council of the European Union (EU) is expressing doubt that the Pandemic Agreement...

MSF’s Access Campaign is an invaluable actor in global health; shutting it down is...

On 20 June, STAT News reported that Médecins Sans Frontières (MSF) is closing down their Access Campaign, effective as of 31 December 2024. It...

Wrapping up 2020 with some noteworthy medicines, law and policy events

Wrapping up the year 2020 can’t happen soon enough. This year, one way or the other, most people on the planet have been affected...

Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...

“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...